Blood mRNA and miRNA transcriptome to predict chronic lung allograft dysfunction

Royer, Pierre-Joseph; Báron, Daniel; Reboulleau, Damien; Tissot, A. N.; Botturi-Cavaillès, K.; Roux, Antoine; Reynaud‐Gaubert, Martine; Kessler, Romain; Mussot, Sacha; Dromer, C.; Brugière, Olivier; Mornex, Jean‐François; Guillemain, R.; Dahan, Marcel; Knoop, Christiane; Pison, Christophe; Koutsokera, Angela; Nicod, Laurent; Brouard, Sophie; Magnan, A.

doi:10.1183/13993003.congress-2015.pa1792

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diversity of these insults as well as the donor and recipient genetic burden assign each patient a unique clinical history. Hence, large-scale gene expression profiling 187,[196][197][198][199] or the powerful systems biology approach, [200][201][202][203] which integrates data sets of different nature, represents promising tools to decipher the complex network of factors involved in the development of CLAD.…”

Section: Discussionmentioning

confidence: 99%

Chronic Lung Allograft Dysfunction

et al. 2016

Self Cite

View full text Add to dashboard Cite

Chronic lung allograft dysfunction (CLAD) is the major limitation of long-term survival after lung transplantation. Chronic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently described restrictive allograft syndrome. Although numerous risk factors have been identified so far, the physiopathological mechanisms of CLAD remain poorly understood. We investigate here the immune mechanisms involved in the development of CLAD after lung transplantation. We explore the innate or adaptive immune reactions induced by the allograft itself or by the environment and how they lead to allograft dysfunction. Because current literature suggests bronchiolitis obliterans syndrome and restrictive allograft syndrome as 2 distinct entities, we focus on the specific factors behind one or the other syndromes. Chronic lung allograft dysfunction is a multifactorial disease that remains irreversible and unpredictable so far. We thus finally discuss the potential of systems-biology approach to predict its occurrence and to better understand its underlying mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Lung Allograft Dysfunction

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…of CLAD using biomarkers via microarrays or RNA sequencing technology of samples collected from blood or BAL, including gene expression profiling, blood mRNA and miRNA transcriptome (95)(96)(97). For the future, genetic risk profiling of lung transplant recipients might be a promising approach to identifying patients at low risk of developing acute rejection and CLAD, which will probably lead to personalized immunosuppressive treatment with reduction of immunosuppressive treatment or the number of medical appointments, thus improving both health care efficacy, and quality of life (98).…”

mentioning

confidence: 99%

Narrative review of the evolution of lung transplant

Makdisi¹,

Cedeno-Rodriguez²

2023

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Background: The first successful human lung transplant was performed approximately six decades ago, but evolution has been slow. It was not until the past two decades that lung transplantation became a more routine procedure with predictable outcomes.Methods: A comprehensive search of the medical literature using Ovid and PubMed search engines was conducted for progression of all aspects of lung transplantation, including surgical techniques, immunosuppression progression, donor selection criteria evolution, recipient criteria evolution, new technology used to support the patient prior and after transplant, along with donor organ management and the Lung Allocation Scoring (LAS) system variables and their impact on outcomes after lung transplantation.Conclusions: Advancement has been multifactorial in all phases of lung transplantation: in the preoperative phase with better selection criteria, better nutrition, and better pulmonary and physical rehabilitation; in the perioperative phase with improvement of surgical techniques, immunosuppression drugs, development of mechanical circulatory support, and preservation technology; and in the postoperative phase with better understanding of immune rejection and better management of long-term complications.All these progressions have been fundamental to the current success of lung transplantation.

show abstract

Blood mRNA and miRNA transcriptome to predict chronic lung allograft dysfunction

Cited by 2 publications

References 0 publications

Chronic Lung Allograft Dysfunction

Chronic Lung Allograft Dysfunction

Narrative review of the evolution of lung transplant

Contact Info

Product

Resources

About